Geoffrey R. Oxnard

28.8k total citations · 11 hit papers
299 papers, 15.2k citations indexed

About

Geoffrey R. Oxnard is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Geoffrey R. Oxnard has authored 299 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 232 papers in Pulmonary and Respiratory Medicine, 159 papers in Cancer Research and 155 papers in Oncology. Recurrent topics in Geoffrey R. Oxnard's work include Lung Cancer Treatments and Mutations (199 papers), Cancer Genomics and Diagnostics (155 papers) and Colorectal Cancer Treatments and Studies (53 papers). Geoffrey R. Oxnard is often cited by papers focused on Lung Cancer Treatments and Mutations (199 papers), Cancer Genomics and Diagnostics (155 papers) and Colorectal Cancer Treatments and Studies (53 papers). Geoffrey R. Oxnard collaborates with scholars based in United States, South Korea and United Kingdom. Geoffrey R. Oxnard's co-authors include Pasi A. Jänne, Cloud P. Paweletz, Mark G. Kris, Vincent A. Miller, Suzanne E. Dahlberg, Marc Ladanyi, William Pao, Kenneth S. Thress, Maria E. Arcila and David M. Jackman and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Geoffrey R. Oxnard

287 papers receiving 15.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Cloud P. Paweletz, Yanan Kuang et al. profile →
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

2016 641 citations Geoffrey R. Oxnard, Ryan S. Alden et al. Journal of Clinical Oncology profile →
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

2018 608 citations Geoffrey R. Oxnard et al. Journal of Clinical Oncology profile →
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

2014 590 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →
Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

2018 513 citations Geoffrey R. Oxnard, Yuebi Hu et al. profile →
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

2016 493 citations Mark M. Awad, Geoffrey R. Oxnard et al. Journal of Clinical Oncology profile →
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

2010 485 citations Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research profile →
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

2011 476 citations Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research profile →
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer

2016 432 citations Adrian G. Sacher, Cloud P. Paweletz et al. profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Geoffrey R. Oxnard, Helena A. Yu et al. profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Lecia V. Sequist, Helena A. Yu et al. profile →

Peers

Countries citing papers authored by Geoffrey R. Oxnard

Since Specialization

Citations

This map shows the geographic impact of Geoffrey R. Oxnard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey R. Oxnard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey R. Oxnard more than expected).

Fields of papers citing papers by Geoffrey R. Oxnard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey R. Oxnard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey R. Oxnard. The network helps show where Geoffrey R. Oxnard may publish in the future.

Co-authorship network of co-authors of Geoffrey R. Oxnard

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey R. Oxnard. A scholar is included among the top collaborators of Geoffrey R. Oxnard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey R. Oxnard. Geoffrey R. Oxnard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA 2021 ·Clinical Cancer Research ·Xiaoji Chen, Dong Zhao, Earl Hubbell, Kathryn N. Kurtzman, Geoffrey R. Oxnard, Oliver Venn, Collin Melton, Christina A. Clarke, Rita Shaknovich, (unknown), (unknown), Michael V. Seiden, Eric A. Klein, Eric T. Fung, Minetta C. Liu	79
2	Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations 2020 ·Cancer Discovery ·Jian Carrot‐Zhang, Giovanny Soca‐Chafre, Nick Patterson, Aaron R. Thorner, Anwesha Nag, Jacqueline Watson, Giulio Genovese, July Rodríguez, (unknown), Luis Corrales, Yoichiro Mitsuishi, Gavin Ha, Joshua D. Campbell, Geoffrey R. Oxnard, Óscar Arrieta, Andrés F. Cardona, Alexander Gusev, Matthew Meyerson	71
3	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) 2020 ·Clinical Cancer Research ·Erin M. Bertino, Ryan D. Gentzler, (unknown), Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, (unknown), Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie J. Lau, Lynette M. Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard	31
4	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas 2018 ·Clinical Cancer Research ·Susan E. Jorge, Antonio R. Lucena‐Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu Kobayashi, Daniel B. Costa	51
5	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis 2018 ·Clinical Cancer Research ·Yuebi Hu, Bryan C. Ulrich, Julianna Supplee, Yanan Kuang, Patrick H. Lizotte, Nora Feeney, Nicolas Guibert, Mark M. Awad, Kwok‐Kin Wong, Pasi A. Jänne, Cloud P. Paweletz, Geoffrey R. Oxnard	290
6	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients 2017 ·Clinical Cancer Research ·Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, (unknown), Jennifer Heng, Nora Feeney, Rebecca J. Nagy, (unknown), Bryan C. Ulrich, (unknown), Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz, Geoffrey R. Oxnard	63
7	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations 2017 ·Clinical Cancer Research ·Helena A. Yu, Alexander I. Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey L. Evans, Ronan J. Kelly, (unknown), Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, (unknown), Anne Keating, Geoffrey R. Oxnard	23
8	Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer 2016 ·Cancer Discovery ·Magda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne, Geoffrey R. Oxnard	114
9	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial 2016 ·Clinical Cancer Research ·Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O’Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne	92
10	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients 2015 ·Clinical Cancer Research ·Cloud P. Paweletz, Adrian G. Sacher, (unknown), Ryan S. Alden, Allison O’Connell, Stacy L. Mach, Yanan Kuang, Leena Gandhi, Paul T. Kirschmeier, Jessie M. English, Lee P. Lim, Pasi A. Jänne, Geoffrey R. Oxnard	177
11	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma 2015 ·Clinical Cancer Research ·Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, Pasi A. Jänne	86
12	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2 2015 ·Cancer Research ·Junko Tanizaki, Dalia Ercan, Marzia Capelletti, Michael Dodge, Chunxiao Xu, Magda Bahcall, (unknown), Mohit Butaney, Antonio Calles, Lynette M. Sholl, Peter S. Hammerman, Geoffrey R. Oxnard, Kwok‐Kin Wong, Pasi A. Jänne	30
13	Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA breakdown → 2014 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Stacy L. Mach, Allison O’Connell, Melissa M. Messineo, Jason J. Luke, Mohit Butaney, Paul T. Kirschmeier, David M. Jackman, Pasi A. Jänne	590
14	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations 2012 ·Clinical Cancer Research ·Natasha Rekhtman, Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, André L. Moreira, William D. Travis, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi	289
15	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma 2011 ·Clinical Cancer Research ·Mai He, Marzia Capelletti, Khédoudja Nafa, Cai‐Hong Yun, Maria E. Arcila, Vincent A. Miller, Michelle S. Ginsberg, Binsheng Zhao, Mark G. Kris, Michael J. Eck, Pasi A. Jänne, Marc Ladanyi, Geoffrey R. Oxnard	109
16	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes 2011 ·Journal of Clinical Oncology ·Geoffrey R. Oxnard, Binsheng Zhao, Camelia S. Sima, Michelle S. Ginsberg, Leonard P. James, Robert A. Lefkowitz, Pingzhen Guo, Mark G. Kris, Lawrence H. Schwartz, Gregory J. Riely	118
17	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib 2011 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, (unknown), Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller	50
18	Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay breakdown → 2011 ·Clinical Cancer Research ·Maria E. Arcila, Geoffrey R. Oxnard, Khédoudja Nafa, Gregory J. Riely, Stephen B. Solomon, Maureen F. Zakowski, Mark G. Kris, William Pao, Vincent A. Miller, Marc Ladanyi	476
19	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation breakdown → 2010 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller	485
20	A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development 2010 ·Clinical Cancer Research ·Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie W. Rusch, Marc Ladanyi, Naiyer A. Rizvi, Lawrence H. Schwartz	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact